Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003065 · ClinicalTrials.gov registry record · Phase 2
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
A Phase 2 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00003065 is a Phase 2 study that has completed, run by Herbert Irving Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT00003065, a Phase 2 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating patients who have recurrent or metastatic cancer of the cervix.
Interventions
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1997-01 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003065
The ClinicalTrials.gov registry entry for NCT00003065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00003065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003065 about?
NCT00003065 is a clinical study titled "Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating patients who have recurrent or m...
What is the current status of trial NCT00003065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1997-01. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00003065?
The interventions under investigation include: paclitaxel (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003065?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.